小分子酪氨酸激酶抑制剂(tyrosine kinase inhibitors, TKIs)对于表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变的肺癌患者显示出良好的治疗效果。本研究旨在探讨晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者血清EGFR基因突变状态与EGFR-TKIs疗效的关系。. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.